Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint

Por Ravinetto, Raffaella, De Weggheleire, Anja, Dorlo, Thomas P.C., Francque, Sven, Sokkab, An, Pouget, Corinne, Meessen, Bruno, Tabernero, Patricia, Newton, Paul N., Lynen, Lut
Publicado no Trop Med Int Health (2016)

Assessment of blood-brain barrier penetration of miltefosine used to treat a fatal case of granulomatous amebic encephalitis possibly caused by an unusual Balamuthia mandrillaris s...

Por Roy, Sharon L., Atkins, Jane T., Gennuso, Rosemaria, Kofos, Danny, Sriram, Rama R., Dorlo, Thomas P.C., Hayes, Teresa, Qvarnstrom, Yvonne, Kucerova, Zuzana, Guglielmo, B. Joseph, Visvesvara, Govinda S.
Publicado no Parasitol Res (2015)

Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Afri...

Por Omollo, Raymond, Alexander, Neal, Edwards, Tansy, Khalil, Eltahir AG, Younis, Brima M, Abuzaid, Abuzaid A, Wasunna, Monique, Njoroge, Njenga, Kinoti, Dedan, Kirigi, George, Dorlo, Thomas PC, Ellis, Sally, Balasegaram, Manica, Musa, Ahmed M
Publicado em 2011